Pheast
Blood & Organ Banks · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
168 Waverley St Apt 9, Palo Alto, Califo...Website
www.pheast.comRevenue
$5.1 MillionIndustry
About Pheast
Pheast Therapeutics is focused on developing innovative innate immune checkpoint inhibitors, particularly anti-CD24, to enhance macrophage activity against aggressive cancers. The company has discovered a novel 'don't eat me' signal, CD24, which is prevalent in ovarian and breast cancers, and is advancing its first-in-class antibody, PHST001, through Phase 1 clinical trials. Utilizing a proprietary discovery platform, Pheast aims to create tumor-specific therapies and develop clinical biomarker strategies to complement existing cancer treatments. Led by experts in cancer biology, Pheast is dedicated to providing better treatment options for patients with challenging cancers.Explore more
SIC Code 28,283NAICS Code 32,325Show morePheast Org Chart
Compare Similar Companies to Pheast
Compare insights from companies similar to Pheast, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Pheast Tech Stack
A closer look at the technologies used by Pheast
Top Blood & Organ Banks Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pheast
Sign Up For FreeTo access detailed company insights
Pheast Therapeutics is focused on developing innovative innate immune checkpoint inhibitors, particularly anti-CD24, to enhance macrophage activity against aggressive cancers. The company has discovered a novel 'don't eat me' signal, CD24, which is prevalent in ovarian and breast cancers, and is advancing its first-in-class antibody, PHST001, throu... Read More